



Intra-Cellular Therapies (USA): Constituent Deletion

Changes in Russell Equal Weight Index Series

31 March 2025

Subject to the completion of the acquisition of Intra-Cellular Therapies (USA, constituent) by Johnson & Johnson, please see details of affected indexes and effective dates below:

Index	Effective From Start of Trading
Russell 1000 Equal Weight	03 April 2025*
Russell Midcap Equal Weight	03 April 2025

*In the absence of an active trading market, Intra-Cellular Therapies will be removed at the acquisition terms of 132.00 USD per each share held.

For further information please contact FTSE Russell Client Services at info@ftserussell.com or call:

Australia	+61 (0) 2 7228 5659
Hong Kong	+852 2164 3333
Japan	+81 3 6441 1430
London	+44 (0) 20 7866 1810
New York	+1877 503 6437

Alternatively please visit our website at lseg.com/ftse-russell